The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPathfinder Minerals Regulatory News (PFP)

  • This share is currently suspended. It was suspended at a price of 0.275

Share Price Information for Pathfinder Minerals (PFP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.275
PFP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update Re Issue of Equity

28 May 2020 15:16

RNS Number : 2655O
Pathfinder Minerals Plc
28 May 2020
 

28 May 2020

Pathfinder Minerals Plc

("Pathfinder" or the "Company")

 

Update Re Issue of Equity

 

Further to the Issue of Equity announcement released by the Company on 11 May 2020, Pathfinder has agreed, following discussions with its broker, to amend the terms of the placing and subscription to align pricing closer to the Company's current share price.

In aggregate, the same quantum of gross proceeds of £250,000 is still to be raised via a placing and subscription, which will now be for 38,461,538 new ordinary shares of 0.1p each in the Company ("Ordinary Shares"), reflecting an issue price of 0.65p per share (the "Fundraise"), being equal to the closing mid-market share price of the Company on 27 May 2020.

 

As previously announced, the net proceeds will provide the Company with additional working capital to pursue the recovery of an interest in Mining Concession 4623C, as well as for general working capital purposes. When added to the expected cash inflow from the convertible loan note instrument announced on 3 April 2020, the Board believes the Company should have sufficient funds on its current cost basis to continue operations into 2021.

 

Annual Broker Fees

 

As previously announced, the Company has appointed Novum Securities Limited ("Novum") as its broker. The Company has agreed with Novum to settle its annual broking fee in advance through the issuance of 3,076,923 new Ordinary Shares to Novum (the "Fee Shares").

 

Admission to trading on AIM

 

The Company will apply for the admission of the 38,461,538 new Ordinary Shares to be issued pursuant to the Fundraise (the "Fundraise Shares") and the 3,076,923 Fee Shares to trading on AIM and this is expected to take place on or around 3 June 2020 ("Admission"). 

 

Following Admission, the Company's issued share capital will consist of 360,223,831 Ordinary Shares with no Ordinary Shares held in treasury. Therefore, the above figure of 360,223,831 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Pathfinder under the FCA's Disclosure and Transparency Rules.

 

Richard Jennings, who, together with his related parties, Align Research and C. A. Jennings, currently holds a total of 9.1 percent of the Company's issued share capital, has committed to subscribe for 3,076,923 Fundraise Shares on the revised terms. Following Admission of the Fundraise Shares and the Fee Shares, Align Research and related parties - R. S. and C. A. Jennings, will have an enlarged shareholding of 32,076,923 Ordinary Shares, representing 8.9 percent of the then enlarged issued share capital of the Company. 

 

Issue of Warrants

 

Pursuant to the Fundraise, the Company has also issued to the recipients of the Fundraise Shares warrants to subscribe for one new Ordinary Share for every one Fundraise Share subscribed for, with an exercise price of 1.5p (the "Warrants"), 50 percent of which are proposed to be allotted and issued by the Company pursuant to the Fundraise by Admission, and 50 percent to be issued conditional upon the passing of the necessary resolutions by shareholders at the next General Meeting of the Company authorising their allotment (the "GM Approval"), exercisable for a period of two years from the date of the admission to trading on AIM of the Fundraise Shares.

 

In connection with the Fundraise, the Company has agreed to issue Novum warrants over 3,230,769 Ordinary Shares (previously 1,800,000 Ordinary Shares) on the same terms as above (the "Novum Warrants"). Warrants over a further 153,846 Ordinary Shares (previously 200,000 Ordinary Shares) will be issued to another corporate adviser in relation to the Fundraise (the "Other Adviser Warrants"). The issuance of the Novum Warrants and the Other Adviser Warrants will also be subject to GM Approval.

 

 

Dennis Edmonds, Chief Executive Officer of Pathfinder, commented:

 

"We are encouraged that all of the investors have maintained their commitment to the Fundraise, rebased to yesterday's closing share price. We continue to work towards a commercial resolution to the licence dispute."

 

Enquiries:

Pathfinder Minerals Plc

Dennis Edmonds, Chief Executive Officer

Tel. +44 (0)20 3440 7775

 

Strand Hanson Limited (Nominated & Financial Adviser)

James Spinney / Ritchie Balmer / Jack Botros

Tel. +44 (0)20 7409 3494

 

Vigo Communications (Public Relations)

Ben Simons / Simon Woods

Tel. +44 (0)20 7390 0234

Email. pathfinderminerals@vigocomms.com

 

Novum Securities Limited (Corporate Broker)

Colin Rowbury / Jon Belliss

Tel. +44 (0)20 7399 9400

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEFLFLSEEITFII
Date   Source Headline
6th Jun 20223:52 pmRNSNotice of AGM
6th Jun 20223:50 pmRNSFinal Results for the Year Ended 31 December 2021
6th May 20223:19 pmRNSExtension of Certain Share Options and Warrants
6th May 20223:10 pmRNSIssue of Equity and TVR
12th Apr 20227:00 amRNSCompany Strategy Update
10th Dec 202111:05 amRNSSecond Price Monitoring Extn
10th Dec 202111:00 amRNSPrice Monitoring Extension
10th Dec 20217:00 amRNSUpdate re Bilateral Investment Treaty Claim
4th Oct 20214:30 pmRNSGrant of Share Options
14th Sep 20217:00 amRNSHalf-year Results
19th Jul 20213:13 pmRNSChange of Registered Office
30th Jun 202111:47 amRNSResult of Annual General Meeting
29th Jun 20217:00 amRNSUpdate re Bilateral Investment Treaty Claim
24th Jun 202111:00 amRNSGrant of Share Options
9th Jun 202110:38 amRNSGrant of Share Options
7th Jun 20217:02 amRNSChange of Adviser
7th Jun 20217:01 amRNSNotice of AGM
7th Jun 20217:00 amRNSFinal Results
27th May 20217:00 amRNSHolding(s) in Company
25th May 20217:00 amRNSDirector Appointment
21st May 20217:00 amRNSUpdate re Bilateral Investment Treaty Claim
12th May 20215:40 pmRNSHolding(s) in Company
12th May 202112:33 pmRNSHolding(s) in Company
4th May 20213:40 pmRNSIssue of Equity and Total Voting Rights
12th Apr 20217:00 amRNSUpdate re Bilateral Investment Treaty Claim
1st Apr 20215:58 pmRNSGrant of Share Options
1st Apr 20215:57 pmRNSHolding(s) in Company
29th Mar 20212:07 pmRNSResult of General Meeting - Replacement
29th Mar 202112:29 pmRNSResult of General Meeting
17th Mar 20217:00 amRNSDirectorate Change
10th Mar 20217:00 amRNSNotice of General Meeting
1st Mar 202110:59 amRNSChange of Auditor
19th Feb 20213:34 pmRNSStrategy Update, Placing, CLN Amendment & TVR
25th Jan 202111:05 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
20th Jan 202112:22 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSDirector/PDMR Shareholding
6th Jan 20212:01 pmRNSPrice Monitoring Extension
29th Dec 20204:32 pmRNSDirector/PDMR Shareholding
16th Dec 20203:32 pmRNSBilateral Investment Treaty Claim – Legal Opinion
11th Dec 20207:00 amRNSUpdate Re Mining Licence
30th Nov 20207:00 amRNSRecovery of Costs Awards
18th Nov 20205:15 pmRNSHolding(s) in Company
12th Nov 20207:00 amRNSCLN Conversion and Final Settlement
5th Nov 202011:32 amRNSCLN Maturity Date
4th Nov 20207:00 amRNSIssue of Warrants
2nd Nov 20207:00 amRNSCompany Strategy Update
30th Oct 20207:00 amRNSHalf-year Report
29th Oct 20207:00 amRNSChange of Admission Date
22nd Oct 20207:05 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.